E139 – SGLT2 inhibitors for kidney and heart disease

episode

Australian Prescriber Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Analyzing Cody's Interview | PENTA a Made Man? 40 min · 20 Sep 2026 · Busted Open

NPR News: 09-20-2026 12PM EDT 5 min · 20 Sep 2026 · NPR News Now

12PM ET 09/20/2026 Newscast 3 min · 20 Sep 2026 · Fox News Hourly Update

Senator Reveals Insider Secrets Against Trump; This Will Blow Your Mind 36 min · 20 Sep 2026 · IHIP News

Supermarket showdown - the battle of the election policy 21 min · 20 Sep 2026 · The Detail

“Creep Stepdad” gets 10-Year-Old Stepdaughter PREGNANT, Mom then tries to Cover Whole Thing Up 44 min · 20 Sep 2026 · The Criminal Makeup

Report any issue

Source

Recorded19 Sep 2022

Publisheraustralianprescriber.libsyn.com ↗

Handlerec:9752945

Show notes

Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease. Jo Cheah finds out more from cardiologist John Atherton.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related